Articles
Drugs-generic-2

End-of-life treatments: what will NICE accept?

As consultation on the 'new' Cancer Drugs Fund closes this week, Leela Barham reviews the impact of England's guidance on end-of-life treatments and the implications of these broader changes.

Articles
Hooray for patient engagement teams

Hooray for patient engagement teams

Patient advocate Andrew Schorr welcomes pharma's efforts to listen to, and work with, patients and calls for company-wide support for these new initiatives.

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D